Last checked at 
LONDON (Alliance News) - NetScientific PLC on Friday said its portfolio company ProAxsis has registered a CE Mark which will allow it to begin commercialisation for its respiratory test in Europe.
The healthcare intellectual-property firm said ProAxsis registered the CE Mark for its ProteaseTag Active Neutrophil Elastase Immunoassay, a treatment for chronic respiratory diseases including cystic fibrosis.
The CE Mark means ProAxsis is now able to sell its immunoassay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein.
"Achieving CE Mark for its immunoassay demonstrates the company's clear commitment to delivering first-class quality products to physicians and their patients who suffer from chronic respiratory diseases," said NetScientific Chief Executive Francois Martelet.
Shares in NetScientific were up 1.3% at 78.50 pence on Friday morning.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
